Poster Session II p<0.1), while remitted CHR had dMMN amplitude (-5.11 ± 0.35μv, p=0.47) comparable to HC. There was no significant main effect of laterality or interaction of group × laterality. In non-remitted CHR subjects, dMMN amplitude was significantly correlated with Glx level (r=-0.47, p<0.01) and with GABA level (r=-0.38, p<0.05) in the mPFC. However, the correlation of dMMN amplitude with Glx or GABA levels was not significant among either HC or remitted CHR. Discussion: In line with previous studies, reduced dMMN amplitude distinguished between remitted and non-remitted CHR subjects, with remitted CHR not different from HCs. Our finding further supports the idea that reduced dMMN amplitude could be a candidate biomarker for predicting outcome in CHR. More importantly, we linked the reduced dMMN amplitude in non-remitted CHR to their Glx and GABA levels in mPFC, the region identified as one of dMMN sources (responsible for attention switching) thus supporting the idea that NMDA-mediated disruptions may play a key role in predicting psychosis and functional outcome. Background: Environmental risk factors that operate at maternal, foetal and post-natal levels, causing immune activation are known risk factors for schizophrenia. How this risk is transduced is unknown but one plausible disease mechanism may be through immune activation perturbing central nervous system growth factor systems, such as the epidermal growth factor (EGF) system critical to neuronal differentiation, maturation and plasticity, altering neurodevelopment. These interactions between EGF and immune systems may involve specific critical brain regions and not others.
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Methods:
The expression of candidate genes from EGF and immune systems and related signalling pathways, including ligands, receptors and intermediary molecules, were examined in post-mortem dorsolateral prefrontal (DLPFC) (n=114 genes) and orbitofrontal cortical (OFC) (n=105 genes) tissues, from schizophrenia and mood disorder patients and healthy controls (n=68), using the Fluidigm Biomark qRT-PCR platform. Data were analysed by ANOVA or corresponding non-parametric test (KruskalWallis) in GraphPad Prism 6/7 statistical software and p values were adjusted for multiple testing (Benjamini-Hochberg).
Results: In DLPFC, 68 genes were significantly differently expressed between diagnostic groups. In comparison to healthy controls, 60 genes were differentially expressed in schizophrenia and 14 in the mood disorder group. Collectively these differentially expressed genes belonged predominantly to ERBB signalling and associated MAPK, PI3K and MTOR pathways and with immune pathways involving toll like receptor (TLR), TNF, nuclear factor kappa B (NFB), JAK-STAT, and complement signalling. Although there was some overlap the expression profiles in schizophrenia and mood disorder differed considerably. There were genes (n=15) with significantly lowered expression in both patient groups compared to controls which belonged predominantly to immune pathways such as TNF and TLR. However, 36 genes were differentially expressed between schizophrenia and mood disorder, all of them having lower expression in schizophrenia, predominantly representing pathways PI3K/MTOR, MAPK, TLR and TNF signalling via NFKB. Gene expression in EGF system signalling via MAPK and PI3K pathways, and interleukin signalling via JAK-STAT were significantly lower in schizophrenia than in mood disorder and healthy controls. ErbB4 was the only gene significantly elevated in a patient group (mood disorder) compared to the controls. In comparison to DLPFC, only five genes out of the 105 examined were differentially expressed between the diagnostic groups in OFC, which belonged to NFB, TLR, JAK-STAT and growth factor signalling pathways. In comparison to healthy controls all were differentially expressed in schizophrenia and three genes in the mood disorder group. The expression of most genes was decreased in the patient groups compared to control subjects in both brain regions. Discussion: We conclude that there is a prominent regional difference in the expression of EGF and immune system markers, identifying the DLPFC as a region of high activity for the interaction between these two systems relative to the OFC. In this region, the differing profiles of gene expression between schizophrenia and mood disorder involved EGF signalling pathways including PI3K/MTOR and MAPK along with immune pathways such as TNF, TLR and JAK-STAT signalling, possibly reflecting variant pathological processes involving immune and EGF system signalling between these sets of disorders. Background: Higher glutamate levels are found in the anterior cingulate cortex (ACC) of non-responder (NR) patients with schizophrenia in cross-sectional studies. However, it remains unclear if this reflects the pathophysiology of NR patients or the effect of antipsychotics and illness chronicity. Also, no previous study has assessed if levels of GABA in the ACC and glutamate in the thalamus are abnormal in NR patients from illness onset. To investigate this, we examined antipsychotic-naïve schizophrenia (SCZ) patients before and after treatment. Methods: Longitudinal study of 38 initially antipsychotic naïve SCZ patients and 34 matched healthy controls (HC) assessed at baseline, after 1.5 months (NSCZ=29, NHC=33), and 6 months (NSCZ=26, NHC=28) of treatment. Patients were treated with aripiprazole for the first 1.5 months (open label). Hereafter, treatment could be modified. Responders (R) and non-responders (NR) were assessed using the Andreasen criteria. Glutamate spectra in the ACC and left thalamus were acquired with a PRESS sequence, and GABA spectra in the ACC with a MEGA-PRESS on a 3T MR scanner. Results: First, the trajectory of glutamate/Cr and GABA/Cr levels were evaluated in SCZ patients and HC with a linear mixed model. In the left thalamus, a significant time*group interaction was observed (p=0.01) due to higher levels of glutamate/Cr in SCZ patients at baseline (p=0.03), but not after 1.5 and 6 months' treatment as compared with HC. In the ACC, a significant main effect of group was found for both glutamate/Cr (p=0.04) and GABA/Cr (p=0.003) due to lower levels in SCZ patients at all examinations, and the time*group interactions were non-significant. Secondly, we investigated if baseline levels of glutamate/Cr and GABA/Cr differed in NR patients after 1.5 and 6 months' treatment using ANOVA. In the left thalamus, NR patients after both 1.5 and 6 months had significantly higher baseline glutamate/Cr compared with HC (P1.5months=0.03 and P6months<0.05), whereas R and HC did not differ. In the ACC, NR after 1.5 months showed a trend for lower GABA/Cr at baseline (p=0.06), and in NR after 6 months baseline GABA/Cr was significantly lower compared with HC (p=0.03), whereas R and HC did not differ. In the ACC, there was no baseline difference in glutamate/Cr of NR patients after 1.5 and 6 months compared with HC. Discussion: The findings indicate increased glutamatergic turnover in the left thalamus and decreased GABAergic neurotransmission in the ACC in the pathophysiology of schizophrenia. Treatment normalises glutamate levels in the left thalamus, but does not affect GABA and glutamate levels in the ACC. Importantly, NR patients are characterized by more pronounced glutamatergic and GABAergic disturbances in the antipsychotic-naïve state. Compounds that modify glutamatergic and GABAergic neurotransmission might have therapeutic potential in this subgroup. Background: Offspring of patients with schizophrenia and bipolar disorder are at increased risk to develop psychopathology. It has been suggested that the development of these disorders may be a result of early neurodevelopmental abnormalities. The intracranial volume (ICV) is a direct marker for neurodevelopment in the early years, as ICV reaches 90% of its full size around the age of five. Interestingly, a smaller ICV is more consistently found in SZ patients, compared to controls, than in bipolar disorder patients. The offspring of these two patients group may provide important information on the putative neurodevelopmental trajectory underlying the development of these disorders. We compared ICV between offspring of at least one parent with SZ (SZo) or BD (BDo) and control offspring (Co) in relation to IQ and the presence of psychopathology. Methods: A large sample of children and adolescents (8-18 years old; 54 SZo, 90 BDo, and 46 Co) was included. T1-weighted (3-Tesla) MRI brain scans were available for 146 participants. Group differences in ICV, global and local brain measures, psychopathology (K-SADS-PL, CBCL/6-18), IQ (WISC-III/WAIS-III), and their interactions were analyzed. FreeSurfer-5.3.0 was used for subcortical and cortical volume, cortical thickness, and cortical surface area estimations. Groups were compared using linear mixed effects modeling, corrected for family dependencies. FDR-correction was applied. Results: Our main finding was that ICV was significantly smaller in SZo, compared to BDo and Co. IQ was significantly lower in both SZo and BDo, relative to Co, but could not explain the smaller ICV in SZo. ICV was also not explained by psychopathology, even though there was no significant difference in 'any psychopathology' between SZo and BDo. There was however some illness specificity as BDo had a higher prevalence of 'any mood disorder' as compared with Co, and SZo had a higher prevalence of major depressive disorder and autism spectrum disorders as compared with BDo and Co. After correcting for ICV, the cortex was significantly thinner in SZo compared to BDo and Co, and BDo had larger lateral ventricles than
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